Michielsens, Celia A J <br/><br/>
Dose reduction and withdrawal strategy for TNF-inhibitors in psoriatic arthritis and axial spondyloarthritis: design of a pragmatic open-label, randomised, non-inferiority trial.  [electronic resource] 

 -  Trials  Jan 2020 
 - 90 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1745-6215 
<br/><br/><label>Standard No.: </label>10.1186/s13063-019-4000-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab--adverse effects<br/>Adolescent<br/>Adult<br/>Antibodies, Monoclonal--adverse effects<br/>Arthritis, Psoriatic--drug therapy<br/>Bayes Theorem<br/>Case-Control Studies<br/>Cost-Benefit Analysis<br/>Dose-Response Relationship, Drug<br/>Etanercept--adverse effects<br/>Follow-Up Studies<br/>Humans<br/>Infliximab--adverse effects<br/>Netherlands--epidemiology<br/>Quality of Life<br/>Research Design<br/>Severity of Illness Index<br/>Spondylarthritis--drug therapy<br/>Tumor Necrosis Factor Inhibitors--adverse effects<br/>Young Adult